Search
Pegloticase
go.drugbank.com/drugs/DB09208ApprovedInvestigationalPegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies. … [L42425] Pegloticase has a longer terminal elimination half-life thanks to the addition of a polyethylene glycol (PEG) group.
Categories: Compounds used in a research, industrial, or household settingAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 75MG/ML, PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 150 MG/MLLevobupivacaine
go.drugbank.com/drugs/DB01002ApprovedInvestigationalWithdrawnIn particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. … It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal
Synonyms: L-BUPIVACAINE, L-(−)-bupivacaineDidanosine
go.drugbank.com/drugs/DB00900ApprovedInvestigationalThis modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. … A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseEtanercept
go.drugbank.com/drugs/DB00005ApprovedInvestigationalIt is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). … Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.
Categories: Biologics for Rheumatoid Arthritis TreatmentProducts: Enbrel Solution for Injection in a Pre-filled Pen 50mg, Enbrel Solution for Injection in a Pre-filled Syringe 50mgVaricella zoster vaccine (live/attenuated)
go.drugbank.com/drugs/DB10318ApprovedInvestigationalPHN can last for days, months, or even years following resolution of shingles. … as shingles (or Herpes Zoster).
Categories: Antiinfectives for Systemic UseOliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse … [A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S.
Antihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalPEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein. … PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529].
Categories: Compounds used in a research, industrial, or household settingProducts: ADYNOVATE 3000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION, ADYNOVATE 250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTIONLumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigationalLumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. … [FDA Label] This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi.